<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03848052</url>
  </required_header>
  <id_info>
    <org_study_id>ESMEAMLC</org_study_id>
    <nct_id>NCT03848052</nct_id>
  </id_info>
  <brief_title>Evolution of the Therapeutic Care in Advanced or Metastatic Lung Cancer From 2013 (ESME-AMLC)</brief_title>
  <official_title>Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Advanced or Metastatic Lung Cancer in France From 2013</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ESME AMLC Data Platform is a multi-center real life database using a retrospective data
      collection process in France over 36 sites. This database compiles data from Patient's
      Electronic medical records (EMR), inpatient Hospitalisation records and Pharmacy records.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This database compiles data from Patient's Electronic medical records (EMR), inpatient
      Hospitalisation records and Pharmacy records.

      Patient Database: Patient-related data integrates data from non-structured sources
      (electronic medical records), such as patient medical records and reports of multidiscipline
      team meetings. It can provide information on patient demographics, primitive tumour,
      relapses, pathology reports, metastatic disease, therapeutic care/settings and withdrawal
      reasons when applicable and clinical events.

      Treatment Database: Pharmacy records-related data is a structured database including all data
      pertaining to medications prescribed and dispensed by pharmacies within each center,
      specifically chemotherapy and co-prescriptions. It does not contain information on products
      that are prescribed or delivered outside of the center. From each center's pharmacy database,
      information on systemic treatment patterns (dates, pharmaceutical forms, treatment protocols,
      etc.) can be obtained.

      Hospitalization Database: Hospitalisation-related data is a structured and systematic
      database that contains all medical data reported related to any hospitalisation in the
      contributing center, and is used to bill the French National Health Insurance Fund (Assurance
      Maladie). It provides information on patient entry and discharge dates as well as diagnostic
      and therapeutic procedures performed, including radiotherapy and surgery.

      Data imported into the final database are controlled, recoded, and harmonized before import
      according to a data management plan. All coding procedures are predefined by the data
      manager. There is no transmission of individual data; all data are centralized within each
      center using a shared anonymous format. All data are exclusively obtained retrospectively; no
      attempts are made to recover non available data from the patient's medical record by
      contacting healthcare providers or patients.

      ESME AMLC Data Platform aims to be a clinical and therapeutic database centralising existing
      and available data from different sources used in the contributing centers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient characteristics</measure>
    <time_frame>Baseline</time_frame>
    <description>Aage in years, Tobacco consumption, other exposures, Legal recognition as occupational disease, Medical history, History of other cancer, weight in kg and performance status (ECOG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tumor characteristics</measure>
    <time_frame>Baseline</time_frame>
    <description>Staging, Tumor size, sampling Method, histological type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment patterns</measure>
    <time_frame>From Baseline until 2024 (yearly basis)</time_frame>
    <description>Drug, therapeutic class, treatment duration at each n treatment line</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>From date of diagnosis or first treatment until the date of death from any cause. Follow up until 2024</time_frame>
    <description>Assessment of overall survival through treatment lines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median surrogate endpoints for overall survival</measure>
    <time_frame>From start date of the nth treatment line until the date of first applicable event. Follow up until 2024</time_frame>
    <description>Surrogate endpoints (Progression-free Survival, Time to Progression, Time to Next Treatment) at each n treatment line.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">26000</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients treated for an ovarian cancer in the 36 French contributing
        centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patient treated in first -line treatment for a lung cancer over the selection period
             in one of the participating center

          -  Patient receiving a therapeutic care defined as chemotherapy, targeted therapy,
             immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic
             procedure)

        Exclusion criteria

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu Robain, MD, PhD</last_name>
    <phone>0033144235553</phone>
    <email>m-robain@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gaëtane Simon, Msc</last_name>
    <phone>0033173797300</phone>
    <email>g-simon@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Paul Papin</name>
      <address>
        <city>Angers,</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève PERROCHEAU</last_name>
      <phone>+33 2 40 67 99 77</phone>
      <email>genevieve.perrocheau@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Loïc CAMPION</last_name>
      <email>loic.campion@ico.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne JAFFRE</last_name>
      <phone>+33 5 56 33 78 48</phone>
      <email>a.jaffre@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Valérie GUIZARD</last_name>
      <phone>+33 2 31 45 52 45</phone>
      <email>av.guizard@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MOURET-REYNIER</last_name>
      <phone>+33 4 73 27 81 37</phone>
      <email>marie-ange.mouret-reynier@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christos CHOUAID</last_name>
      <phone>+33 1 57 02 20 70</phone>
      <email>christos.chouaid@chicreteil.fr</email>
    </contact>
    <contact_backup>
      <last_name>David MAHN</last_name>
      <phone>+331 57 02 26 14</phone>
      <email>David.Manh@chicreteil.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick ARVEUX</last_name>
      <phone>+33 3 80 73 75 11</phone>
      <email>parveux@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata CUCCHI</last_name>
      <phone>+33 3 20 29 59 47</phone>
      <email>m-cucchi@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas BACHELOT</last_name>
      <phone>+33 4 78 78 26 54</phone>
      <email>thomas.bachelot@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilian LABORDE</last_name>
      <phone>+33 4 91 22 35 10</phone>
      <email>LABORDEL@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer Montpellier / Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie DELAINE</last_name>
      <phone>+33 4 67 61 47 39</phone>
      <email>stephaine.delaine@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE</last_name>
      <phone>+33 3 89 64 73 96</phone>
      <email>debieuvred@ch-mulhouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Arnaud MULHOUSE</last_name>
      <phone>+33 3 89 64 67 53</phone>
      <email>etiennea@ghrmsa.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest - René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève PERROCHEAU</last_name>
      <phone>+33 2 40 67 99 77</phone>
      <email>genevieve.perrocheau@ico.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Loïc CAMPION</last_name>
      <email>loic.campion@ico.unicancer.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel CHAMOREY</last_name>
      <phone>+33 4 92 03 15 29</phone>
      <email>emmanuel.chamorey@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne BRAIN</last_name>
      <phone>0033144324685</phone>
      <email>etienne.brain@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien PARENT</last_name>
      <phone>+33 3 26 50 42 76</phone>
      <email>damien.parent@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès LOEB</last_name>
      <phone>+33 2 32 08 22 80</phone>
      <email>agnes.loeb@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne BRAIN</last_name>
      <phone>+33 1 47 11 15 15</phone>
      <email>etienne.brain@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel VELTEN</last_name>
      <phone>+33 3 88 25 24 53</phone>
      <email>mvelten@strasbourg.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine BERCHERY</last_name>
      <phone>05 31 15 50 60</phone>
      <email>Berchery.Delphine@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine LAURENT</last_name>
      <phone>+33 3 83 59 83 32</phone>
      <email>c.laurent@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DEJEAN</last_name>
      <phone>+33 1 42 11 46 49</phone>
      <email>valerie.dejean@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Muriel MONS</last_name>
      <phone>+33 1 42 11 60 11</phone>
      <email>muriel.mons@gustaveroussy.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>observational study</keyword>
  <keyword>survival</keyword>
  <keyword>real world data</keyword>
  <keyword>real life setting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

